Ahmed Tarek Aboughalia

Dr. Ahmed Tarek Aboughalia

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
TCTawanda Chivese
Tawanda Chivese
OMOmran A.H. Musa
Omran A.H. Musa
GHGeorge Hindy
George Hindy
NANoor Al-Wattary
Noor Al-Wattary
SBSaif Badran
Saif Badran
SDSuhail A.R. Doi
Suhail A.R. Doi

23 August 2022 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
MDMohammad Danjuma
Mohammad Danjuma
Oyelola A AdegboyeOyelola A Adegboye
Oyelola A Adegboye
AAAhmed Tarek Aboughalia
Ahmed Tarek Aboughalia
NSNada Soliman
Nada Soliman
RARuba Almishal
Ruba Almishal
MBMubarak Arriyo Bidmos
Mubarak Arriyo Bidmos
Background: There has been a rising prevalence of polypharmacy among people living with HIV (PLWH). Uncertainty however remains regarding the exact estimates of polypharmacy among these cohorts of patients. Methods: We conducted a systematic search of PubMed; EMBASE, CROI, Cochrane Database of Systematic Reviews; Science Citation Index and Database of Abstracts of Reviews of Effects for studies between 1 January 2000 and 30 June 2021 that reported on the prevalence of polypharmacy (ingestion of > 5 non-ART medications) among PLWH on antiretroviral therapy regimen (ART). Prevalence of polypharmacy among HIV-positive patients on ART with Clopper–Pearson 95% confidence intervals were presented. The heterogeneity between studies was evaluated using [ ] and [ ] statistics. Results: One hundred ninety-seven studies were initially identified, 23 met the inclusion criteria enrolling 55,988 PLWH, of which 76.7% [95% confidence interval (CI): 76.4–77.1] were male. The overall pooled prevalence of polypharmacy among PLWH was 33% (95% CI: 25–42%) ( I2 = 100%, τ2 = 0.9170, p < 0.0001). Prevalence of polypharmacy is higher in the Americas (44%, 95% CI: 27–63%) ( I2 = 100%, τ2 = 1.0886, p < 0.01) than Europe (29%, 95% CI: 20–40%) ( I2 = 100%, τ2 = 0.7944, p < 0.01). Conclusion: The pooled prevalence estimates from this synthesis established that polypharmacy is a significant and rising problem among PLWH. The exact interventions that are likely to significantly mitigate its effect remain uncertain and will need exploration by future prospective and systematic studies. Registration: PROSPERO: CRD42020170071 Plain Language Summary: Background: In people living with HIV (PLWH), what is the prevalence of polypharmacy and is this influenced by sociodemographic factors? Methods and Results: In this systematic review and meta-analysis of 23 studies comprising 55,988 participants, we have for the first time found an estimated polypharmacy pooled prevalence of 33% among PLWH. There was a relatively higher pooled prevalence of polypharmacy among the America’s compared with European cohorts of PLWH. Conclusion: Polypharmacy among PLWH is a rising morbidity that needs urgent intervention both at policy and patient levels of care.

15 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSNuha T. Swaidan
Nuha T. Swaidan
SSSalam Salloum-Asfar
Salam Salloum-Asfar
FPFreshteh Palangi
Freshteh Palangi
KEKhaoula Errafii
Khaoula Errafii
NSNada H. Soliman
Nada H. Soliman
MEMohamed Emara
Mohamed Emara
Although many factors have been identified and used to enhance the iPSC reprogramming process, its efficiency remains quite low. In addition, reprogramming efficacy has been evidenced to be affected by disease mutations that are present in patient samples. In this study, using RNA-seq platform we have identified and validated the differential gene expression of five transcription factors (TFs) (GBX2, NANOGP8, SP8, PEG3,andZIC1) that were associated with a remarkable increase in the number of iPSC colonies generated from a patient with Parkinson's disease. We have applied different bioinformatics tools (Gene ontology, protein–protein interaction, and signaling pathways analyses) to investigate the possible roles of these TFs in pluripotency and developmental process. Interestingly,GBX2, NANOGP8, SP8, PEG3,andZIC1were found to play a role in maintaining pluripotency, regulating self-renewal stages, and interacting with other factors that are involved in pluripotency regulation includingOCT4, SOX2, NANOG,andKLF4. Therefore, the TFs identified in this study could be used as additional transcription factors that enhance reprogramming efficiency to boost iPSC generation technology.

17 November 2023 in Current Problems in Cardiology
Verified
Journal Article
Closed access
MDMohammed Ibn-Mas'UD Danjuma
Mohammed Ibn-Mas'UD Danjuma
ASAseel Abdulrahim Sukik
Aseel Abdulrahim Sukik
AAAhmed Tarek Aboughalia
Ahmed Tarek Aboughalia
MBMubarak Bidmos
Mubarak Bidmos
YAYousra Ali
Yousra Ali
OAOyelola Adegboye
Oyelola Adegboye

27 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RERuba Ebzee
Ruba Ebzee
IAIbrahim Yusuf Abubeker
Ibrahim Yusuf Abubeker
AAAhmed Tarek Aboughalia
Ahmed Tarek Aboughalia
MDMohammad Danjuma
Mohammad Danjuma
Background/Objectives: Despite immune checkpoint inhibitors (ICPIs)’s transformation of lung cancer treatment, pneumonitis remains a potentially serious immune-related adverse event. However, reliable data on the comparative risks of individual ICPIs remain unknown. We conducted this network meta-analysis (NMA) to, therefore, quantify and compare the exact pooled burden of pneumonitis risk across multiple ICPI analogs. Methods: We searched the following databases, PubMed, Embase, Scopus MEDLINE and Cochrane Database of Systematic Reviews, as well as gray literature on Google Scholar for eligible studies reporting on the prevalence of pneumonitis following immune check point inhibitor exposures. Pairwise and network meta-analyses were performed to estimate pooled odds ratios (ORs) for pneumonitis, using placebo as the common comparator. Sensitivity analyses assessed the impact of study quality and combination therapies. Results: A total of 29 studies enrolling 15,271 patients with non-small cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) satisfied the inclusion criteria and are included in the meta-analysis. Pembrolizumab was associated with a significantly increased risk of pneumonitis compared to placebo (odds ratio [OR] = 2.67, 95% confidence interval [CI]: 1.70–4.17), with similar elevated risk observed for sugemalimab (odds ratio [OR] = 2.45, 95% confidence interval [CI]: 1.52–3.95). Nivolumab was associated with increased odds of pneumonitis, although with unstable point estimate (odds Ratio [OR] = 2.69, 95% confidence interval [CI]: 0.64–11.35). Statistical heterogeneity was low (H statistics = 1.34). Atezolizumab and ipilimumab demonstrated modest or uncertain risk. Heterogeneity was low (I2 = 12%), and results were robust to sensitivity analyses. Higher pneumonitis rates were observed in combination regimens. Conclusions: Our analysis demonstrates that pneumonitis risk varies among ICPIs, with pembrolizumab and sugemalimab showing the highest odds. Although the absolute incidence is low, the potential severity of pneumonitis warrants vigilant monitoring. These results should guide clinicians in risk stratification and treatment planning, and they should support the development of standardized reporting criteria and further comparative research.

11 January 2023 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
MDMohammed Ibn-Mas’ud Danjuma
Mohammed Ibn-Mas’ud Danjuma
ASAseel Abdulrahim Sukik
Aseel Abdulrahim Sukik
AAAhmed Tarek Aboughalia
Ahmed Tarek Aboughalia
MBMubarak Bidmos
Mubarak Bidmos
YAYousra Ali
Yousra Ali
OAOyelola Adegboye
Oyelola Adegboye
Background: Patients with heart failure are living longer with the inevitable morbidity of rising medication counts. It remains uncertain what fraction of this ensuing polypharmacy exactly predicts adverse clinical outcomes. Methods: This prospective, cross-sectional study examined case notes and electronic records of patients admitted to Weill Cornell-affiliated tertiary medical institution (Hamad Medical Corporation, Doha, Qatar) with a confirmed echocardiographic and clinical diagnosis of heart failure between January 2018 to January 2022. Each patient's medication census for the past four months was tallied, and a definitional threshold of ≤4, ≥5, ≥10 medications was established. The primary outcome was all-cause mortality within the study period. Other secondary outcomes explored include the number of heart failure-related admissions, the average length of stay, and the need for intensive care unit admission. Results: Out of a total of 7354 patients included in the study, 70% were males with a median age of 59 years (interquartile range [IQR] 48 – 71). The median (IQR) age-adjusted Charlson Comorbidity Index (CCI) was 2 (1 – 5). A total of 1475 (20%) participants died within the study period. Patient cohorts with excessive polypharmacy (≥9 medications) comprising of both heart failure related, and general medications had the highest probability of survival up to 1.6 years compared to those with lower medication thresholds (≤4), the mortality rate decreased by 18% for patients with excessive polypharmacy (≥9 medications) [HR=0.82, 95% CI: 0.71 – 0.94]). There were no differential mortality outcomes between patients with major vs. excessive heart failure-specific polypharmacy (HR 0.95 [0.81 – 1.13], p = 0.59); and (0.74 [0.53 – 1.01], p = 0.059) for major and excessive heart failure specific polypharmacy respectively. Conversely, patients with non-heart failure-related polypharmacy had increased risks of intensive care admissions (aOR=1.78, 95% CI: 1.13 – 2.70). Heart failure patient cohorts with severe and moderate CCI had higher mortality risks (HR=1.18, 95% CI: 1.03 – 1.36) and (HR=1.38, 95%CI: 1.20 – 1.58), respectively, compared to those with mild index. Conclusion: In an examination of a real-world database of patients with chronic heart failure, major non-heart failure-related polypharmacy was associated with an increased risk of intensive care admissions. Excessive polypharmacy (≥9 medications) comprising both heart failure and non-heart failure-related medications was associated with increased rates of survival. This necessitates the need for a more nuanced approach by directing intervention measures at the non-heart failure medication fraction of polypharmacy in these cohorts of patients. Funding: This study was funded by the grant from the medical research center Hamad Medical Corporation, Doha Qatar (MRC-01-21-937). Declaration of Interests: None of the authors has any conflict of interest to declare Ethics Approval: The study Protocol and relevant documentation for access to patient level data for the study was submitted for review to the independent review Board of medical research center Hamad Medical Corporation, Doha Qatar, following which approval given to proceed with the study (MRC-01-21-937)